Central action of Craviten (M-71).
Craviten (M-71) or 2S, 2'S) N, N'-dimethyl-N, N'-bis [1-(3', 4', 5' -trimethoxy-benzoyloxy)-butyl-2]-ethylenediamine dihydrochloride an agent with a strong antiarrhythmic action has practically no effect on the central nervous system of rats and mice. It exerts no effect on the spontaneous motor activity, on amphetamine-stimulated hyperactivity, on rota-red performance, it has no analgesic and anticonvulsant action and does not change the hexobarbital sleeping time. No effects of Craviten were observed on the body temperature in rats and mice. It decreased the arterial blood pressure in rats and stimulated slightly respiration. The hypotensive effect was dose-dependent. The LD50 of the preparation is: rats: 142 mg/kg ip, 15 x 8 mg/kg iv; mice: 550 mg/kg ip; rabbits: 5 x 1 mg/kg iv.
D000661:Amphetamine / Q000494:pharmacology; D000698:Analgesia; D000768:Anesthesia, General; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects*; D005029:Ethylenediamines / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006591:Hexobarbital; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D005029:Ethylenediamines; C030706:butobendin; D006591:Hexobarbital; D000661:Amphetamine